Lung Cancer Among Never-Smokers—A Growing Concern and a New Focus on Early Detection

Doctor holding a clipboard listens to a woman during a consultation.

For decades, lung cancer has been linked with cigarette smoking. But a key shift is gaining attention from researchers and physicians—a growing number of lung cancer cases are occurring in people who have never smoked.

This trend is challenging long-held beliefs about who develops lung cancer and raising important questions about how the disease can be detected earlier.

A Changing Picture of Lung Cancer

Research cited in JAMA suggests that approximately 15% to 20% of lung cancer cases worldwide occur in people who have never smoked. While smoking remains the leading risk factor, scientists are increasingly investigating other causes.

A 2025 study published in Nature examined lung tumors from 871 people who had never smoked. Researchers found that exposure to fine particles in air pollution was associated with genetic changes linked to cancer development.

Another 2025 study published in The Lancet Respiratory Medicine identified rising global rates of lung adenocarcinoma, a common form of lung cancer among never-smokers and highlighted the contribution of air pollution.

Other potential risk factors include secondhand smoke, radon exposure, family history, and certain environmental exposures.

Although never-smokers account for a growing share of lung cancer diagnoses, researchers are still determining whether their overall risk is increasing.

The Challenge of Detecting Lung Cancer Earlier

One concern is that people who have never smoked generally do not qualify for routine lung cancer screening.

Current U.S. guidelines recommend annual low-dose CT scans for adults ages 50-80 with significant smoking histories who currently smoke or quit within the past 15 years.

That leaves many non-smokers outside established screening recommendations, even when other risk factors are presents.

Could Biomarker Blood Tests Help?

Emerging blood-based technologies may offer additional tools for evaluating lung cancer risk and supporting earlier detection.

Cizzle Bio’s CIZ1B Biomarker Blood Test for Lung Cancer measures a cancer-associated protein biomarker in the blood. A 2026 peer-reviewed study published in The Journal of Applied Laboratory Medicine demonstrated promising results for early-stage lung cancer detection, reporting 94% sensitivity and a 97% negative predictive value (NPV) in a clinical sample set involving Stage I and II lung cancer. These findings highlight the potential of CIZ1B to provide physicians with valuable additional information when evaluating patients for lung cancer.

CIZ1B is designed to provide physicians with biomarker information alongside imaging and clinical evaluation, including assessing suspicious nodules identified on imaging.

Looking Beyond Smoking History

The growing recognition of lung cancer among never-smokers reinforces an important message—anyone with lungs can develop lung cancer.

Understanding your personal risk factors, recognizing persistent symptoms, and discussing concerns with a healthcare provider are important steps toward earlier detection.

As research advances, biomarker blood tests like CIZ1B may help physicians make more informed decisions and expand the tools available to identify lung cancer early—when treatment may be most effective.

November is Lung Cancer Awareness Month—a timely reminder that lung cancer can impact anyone, even if they have never smoked. Take time to learn about your risk factors, talk with your healthcare provider, and encourage loved ones to do the same. Greater awareness and earlier detection can save lives.

To learn more about the CIZ1B Biomarker Blood Test for Lung Cancer and its potential role in early detection, visit www.cizzlebio.com.


Cizzle Bio, Inc.

Cizzle Bio, Inc. is a pioneering biotechnology company focused on developing innovative solutions for early lung cancer detection. With a commitment to advancing cancer diagnostics, Cizzle Bio, Inc. collaborates with leading research institutions and healthcare professionals to bring groundbreaking biomarker blood tests to market, aiming to improve patient outcomes and save lives.

https://www.cizzlebio.com
Next
Next

Biomarker blood testing in San Antonio: questions for patients and providers